80 Participants Needed

Care Coordination with Peer Support for Hepatitis C

(ACCELERATE Trial)

Recruiting at 1 trial location
LR
MA
Overseen ByMatthew Akiyama, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Montefiore Medical Center

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new method to assist individuals with Hepatitis C who have recently been released from jail or prison. It focuses on using peer mentors to support these individuals in starting and adhering to their Hepatitis C treatment. One group will receive guidance and assistance from a peer mentor, while the other group will receive usual care without additional support. Eligible participants should have chronic Hepatitis C, speak English or Spanish, and reside in the Upstate area of South Carolina. As an unphased trial, this study provides a unique opportunity to contribute to innovative support strategies for Hepatitis C treatment.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that this peer-based care coordination intervention is safe for individuals with Hepatitis C?

Research shows that people generally have a positive experience with peer mentor support for Hepatitis C. Studies indicate that participants are very satisfied with this support, finding it helpful and easy to accept. For instance, one study found that participants valued advice and assistance from peers who had already completed Hepatitis C treatment. However, specific negative effects of peer mentoring remain largely undocumented.

In similar programs, peer mentors play a crucial role in offering emotional support and helping people access the care they need. Although detailed safety information is not yet available, positive feedback from past studies suggests that peer mentor support is a safe and helpful approach.12345

Why are researchers excited about this trial?

Researchers are excited about the peer mentor approach for hepatitis C because it offers a fresh angle on patient support and treatment readiness. Unlike the standard of care, which often involves passive referrals, this method actively engages patients through personal interaction with a peer mentor. This peer-enhanced intervention is designed to help patients navigate the early stages post-enrollment, assess their readiness for hepatitis C treatment, and address additional needs. By providing a study cell phone for direct communication, it aims to improve patient outcomes through enhanced support and engagement, which could potentially increase treatment adherence and success rates.

What evidence suggests that this peer-enhanced intervention is effective for Hepatitis C care coordination?

Research has shown that peer support can help patients with chronic Hepatitis C (HCV) stay engaged with healthcare services. In this trial, participants in the peer-enhanced intervention arm will receive support from a peer mentor, which studies have found increases the likelihood of starting HCV treatment. This support also results in more people getting tested for HCV and beginning treatment. Peer educators enhance understanding and involvement in HCV care. Overall, these findings suggest that a peer mentor can effectively encourage HCV treatment and care, especially for those recently released from prison. Meanwhile, participants in the standard of care arm will receive passive referral to HCV care.678910

Who Is on the Research Team?

Dr. Alain Harris Litwin, MD ...

Alain Litwin, MD

Principal Investigator

Prisma Health-Upstate

MA

Matthew Akiyama, MD

Principal Investigator

Montefiore Medical Center/Albert Einstein College of Medicine

Are You a Good Fit for This Trial?

This trial is for adults who have chronic Hepatitis C, were released from a NYC jail or NYS prison within the last 6 months, and can communicate in English or Spanish. They must be able to give informed consent and should not have a life expectancy of less than one year.

Inclusion Criteria

I have chronic Hepatitis C with a detectable virus level.
Recently released from a NYC jail or NYS prison (6 months)

Exclusion Criteria

I am unable to understand or sign the consent form.
Life expectancy of less than 1 year

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive HCV treatment and are monitored for treatment initiation and completion

3 months
Regular visits with HCV treatment provider

Sustained Virologic Response (SVR) Assessment

Participants are assessed for sustained virologic response after treatment completion

3 months

Reinfection Assessment

Participants are monitored for potential reinfection after achieving HCV cure

12 months

What Are the Treatments Tested in This Trial?

Interventions

  • Peer mentor
  • Standard of care
Trial Overview The study is testing if having a peer mentor helps people with Hepatitis C get better care after they leave jail compared to just getting the usual healthcare services. It's looking at how well this works by randomly assigning participants to either the new approach with a mentor or standard care.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Peer-enhanced interventionExperimental Treatment1 Intervention
Group II: Standard of carePlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Montefiore Medical Center

Lead Sponsor

Trials
468
Recruited
599,000+

Prisma Health-Upstate

Collaborator

Trials
91
Recruited
47,500+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials
2,658
Recruited
3,409,000+

Published Research Related to This Trial

A qualitative study involving 23 adults with opioid use disorder revealed significant gaps in knowledge about Hepatitis C virus (HCV) prevention and treatment among people who use drugs, highlighting the need for better education and outreach.
Effective linkage to HCV care can be improved through enhanced communication between patients and healthcare providers, as well as by leveraging peer networks, indicating that integrated care approaches are crucial for addressing the needs of this population.
Engagement in the Hepatitis C care continuum among people who use drugs.Tofighi, B., Lee, JD., Sindhu, SS., et al.[2022]
A peer-based recruitment strategy effectively engaged people who inject drugs (PWID) in hepatitis C virus (HCV) testing and treatment, with 91% of participants completing a linkage to care appointment after being recruited.
Factors such as prior HCV treatment and daily injection drug use were positively associated with successful recruitment of network members, highlighting the importance of leveraging existing social networks for improving HCV care access.
Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care.Falade-Nwulia, O., Ward, KM., McCormick, S., et al.[2022]
In a study analyzing 30,729 patients across 20 treatment networks, the presence of peer supporters significantly increased both the initiation (12% increase) and completion (145% increase) of hepatitis C therapy, suggesting that peer support can enhance treatment engagement.
Despite these positive outcomes, there was no significant change in the initiation of therapy among drug users or in the overall virological response, indicating that while peer support is beneficial for engagement, it may not directly impact treatment effectiveness.
Role of peer support in a hepatitis C elimination programme.Jugnarain, DV., Halford, R., Smith, S., et al.[2023]

Citations

1.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/34808487/
Validation of a tool to assess effectiveness of peer-recruitment ...Validation of a tool to assess effectiveness of peer-recruitment for hepatitis C testing and linkage to care among people who inject drugs.
a randomised controlled trial of a peer support interventionIn conclusion, our findings indicate that peer support can improve the engagement of patients with chronic HCV with healthcare services. The ...
Validation of a tool to assess effectiveness of peer- ...Peer-driven interventions offer a promising approach to increasing HCV treatment among people who inject drugs (PWID).
Community engagement and chronic viral hepatitis public ...This review indicated that community-engaged interventions significantly improved HBV vaccine completion, HBV/HCV test uptake, HBV/HCV linkage to care, HBV/HCV ...
Perceived benefits of the hepatitis C peer educatorsPrevious studies have found that peer educators can help increase knowledge and engagement with HIV and HCV care [25,26,27,28,29] and that peer- ...
Peer-assisted telemedicine hepatitis-C treatment for ...Results. Quantitative data (n = 78) indicated patients had high levels of satisfaction with and support from the peers. Three themes were ...
Enhancing Hepatitis C Virus Testing, Linkage to Care, and ...Structured peer mentor support program where mentors previously successfully treated for HCV ... outcomes due to insufficient data.
Peer-Assisted Telemedicine for Hepatitis C (PATHS)We report development and programmatic evaluation of Peer-Assisted Telemedicine for Hepatitis C (PATHS), which utilizes State Opioid Response (SOR) funding.
A Randomized Controlled Trial of Cash Incentives or Peer ...We evaluated the impact of peer-mentors and cash incentives on linkage to HCV treatment and cure in persons with HIV-HCV coinfection who had not ...
LEAVE NO ONE BEHINDPeer. Mentors will support the Peer Support Lead in delivering awareness campaigns using their own lived experience and may also support individuals to access ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security